Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
32
self-reported 11–50 band
Founded
2017
9 years
Legal entities
1
ABR
Office countries
2
2 addresses
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entity
1 brand → 1 confirmed entity
EPIMINDER LIMITED
ABN59616831684
Legal entities
Show as table · Epiminder: 1 registry entity
| EPIMINDER LIMITED | ABN 59616831684 |
|---|---|
| Confirmed matches | 0 of 1 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Epilepsy is a complex neurological condition affecting over 50 million people globally, with a significant part of the patient population not responding to traditional medication. Epilepsy not only imposes chronic, debilitating effects but also subjects patients to the unpredictable nature of when and how seizures might occur. Epiminder Limited is revolutionising epilepsy care with its implantable continuous EEG monitoring (iCEM®) system, the Minder® system. Minder has been granted authorization via the FDA's de novo pathway and is building a commercial presence in the US.
Seizure diaries are often unreliable, the true picture of a patient's condition may be different from what it initially appears. This creates gaps in understanding of what treatments should be deployed to address the patient’s underlying condition. The Minder system will address this gap by unveiling continuous and objective EEG data that would not otherwise been seen.
Like other diagnostic devices used in conditions requiring continuous monitoring of physiological signals (e.g. implantable cardiac monitors and continuous glucose monitors), the Minder system represents a significant leap forward in epilepsy care, providing objective insights that enable informed clinical actions.
Headquartered in Melbourne, Australia, with an office in Dallas, TX, USA, Epiminder is a public company dedicated to advancing neurological health.
Specialties
All 1 specialty
- neurotechnology and neurology
Locations
2
Countries with an office address2 addresses on record
AustraliaprimaryUnited States
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|---|
| Primary country | AU |
All codes: AU US
Addresses
- AUMelbournePrimary
- USDallas
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entity operates under Epiminder?
One Victoria entity on the ABR: EPIMINDER LIMITED (ABN 59 616 831 684), high confidence.
How many people work at Epiminder?
32 counted staff profiles at January 2026, inside the self-reported 11–50 band.
Where does Epiminder have offices?
Two addresses on record across 2 countries. Primary: Melbourne.
Has Epiminder raised funding?
None linked to this brand.
What does Epiminder list as its specialties?
One tag on the brand's own list, among them neurotechnology and neurology.
Which companies are listed alongside Epiminder?
19 profiles list Epiminder as a peer — 93rd percentile in Biotechnology Research. It lists ten peers of its own. Bionics Institute and Optain (Australia) list it back.